Frank L Meyskens

US Patent:

20020137797, Sep 26, 2002

Filed:

Aug 24, 2001

Appl. No.:

09/938846

Inventors:

Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US

International Classification:

A61K031/198

US Classification:

514/564000

Abstract:

The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

US Patent:

20040162353, Aug 19, 2004

Filed:

Feb 17, 2004

Appl. No.:

10/780921

Inventors:

Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US

International Classification:

A61K031/198

US Classification:

514/564000

Abstract:

The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

US Patent:

62588451, Jul 10, 2001

Filed:

Mar 26, 1999

Appl. No.:

9/277688

Inventors:

Eugene W Gerner - Tucson AZ
Frank L. Meyskens - Irvine CA

Assignee:

The Regents of the University of California - Oakland CA
Arizonia Board of Regents Behalf of the University of Arizonia - Tucson AZ

International Classification:

A61K 31195
A61K 3119

US Classification:

514544

Abstract:

Activation of the Ki-ras proto-oncogene is common in colon carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit carcinogen-induced colon carcinogenesis, decrease the frequency of Ki-ras mutations in the azoxymethane-treated rat model, and induce apoptosis in a variety of cell types. Sulindac, as well as other non-steroidal anti-inflammatory agents, are provided in combination with DFMO the prevention and/or treatment of cancers characterized by the expression of an activated Ki-ras. Provided with the present invention are pharmaceutically acceptable compositions that include a non-steroidal anti-inflammatory agent, sulindac, together with an effective amount of difluoromethylornithine.

US Patent:

8329636, Dec 11, 2012

Filed:

May 14, 2010

Appl. No.:

12/780592

Inventors:

Eugene Gerner - Tucson AZ, US
Jason A. Zell - Dana Point CA, US
Christine McLaren - Irvine CA, US
Frank Meyskens - Irvine CA, US
Hoda Anton-Culver - Irvine CA, US
Patricia A. Thompson - Tucson AZ, US

Assignee:

Arizona Board of Regents on Behalf of University of Arizona - Tucson AZ
The Regents of the University of California, a California Corporation - Oakland CA

International Classification:

A01N 61/00

US Classification:

514 1

Abstract:

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.

US Patent:

20160213634, Jul 28, 2016

Filed:

Sep 1, 2015

Appl. No.:

14/841750

Inventors:

- Tucson AZ, US
- Oakland CA, US
Christine E. MCLAREN - Irvine CA, US
Frank L. MEYSKENS - Irvine CA, US
Hoda ANTON-CULVER - Irvine CA, US
Particia A. THOMPSON - Tucson AZ, US

International Classification:

A61K 31/198
A61K 31/192

Abstract:

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.